Postmenopausal Osteoporosis & Bone Mineral Density (BMD)

Significant improvement in BMD at each dose studied (0.625 mg, 0.45 mg, and 0.3 mg) at 24 months1
When prescribing solely for the prevention of postmenopausal osteoporosis, hormone therapy should be considered only for women at significant risk of osteoporosis, and non-estrogen medications should be carefully considered.
All endpoints are statistically significant vs placebo.
Final evaluation was cycle 26 for those who completed the study and the last available evaluation for those who discontinued early. Each cycle was 28 days.
Anteroposterior lumbar spine.
The Health and Osteoporosis, Progestin and Estrogen (HOPE) Study was a double-blind, randomized, placebo- and active-controlled multicenter study of healthy postmenopausal women with an intact uterus. Subjects (mean age 53.3 ± 4.9 years) were 2.3 ± 0.9 years on average since menopause and took one 600 mg tablet of elemental calcium (Caltrate™) daily. Subjects were not given Vitamin D supplements. Prevention of bone loss was assessed by measurement of bone mineral density (BMD), primarily at the anteroposterior lumbar spine (L2 to L4). Secondarily, BMD measurements of the total body, femoral neck, and trochanter were also analyzed.1
  1. Premarin [prescribing information]. New York, NY: Pfizer Inc.; September 2018.